Rapamycin promotes mouse 4T1 tumor metastasis that can be reversed by a dendritic cell-based vaccine

Tien-Jen Lin, Wen Miin Liang, Pei Wen Hsiao, M. S. Pradeep, Wen Chi Wei, Hsin Ting Lin, Shu Yi Yin, Ning Sun Yang

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Suppression of tumor metastasis is a key strategy for successful cancer interventions. Previous studies indicated that rapamycin (sirolimus) may promote tumor regression activity or enhance immune response against tumor targets. However, rapamycin also exhibits immunosuppressant effects and is hence used clinically as an organ transplantation drug. We hypothesized that the immunosuppressive activities of rapamycin might also negatively mediate host immunity, resulting in promotion of tumor metastasis. In this study, the effects of rapamycin and phytochemical shikonin were investigated in vitro and in vivo in a 4T1 mouse mammary tumor model through quantitative assessment of immunogenic cell death (ICD), autophagy, tumor growth and metastasis. Tumor-bearing mice were immunized with test vaccines to monitor their effect on tumor metastasis. We found that intraperitoneal (ip) administration of rapamycin after a tumor-resection surgery drastically increased the metastatic activity of 4T1 tumors. Possible correlation of this finding to human cancers was suggested by epidemiological analysis of data from Taiwan's National Health Insurance Research Database (NHIRD). Since our previous studies showed that modified tumor cell lysate (TCL)-pulsed, dendritic cell (DC)-based cancer vaccines can effectively suppress metastasis in mouse tumor models, we assessed whether such vaccines may help offset this rapamycin-promoted metastasis. We observed that shikonin efficiently induced ICD of 4T1 cells in culture, and DC vaccines pulsed with shikonin-treated TCL (SK-TCL-DC) significantly suppressed rapamycin-enhanced metastasis and Treg cell expansion in test mice. In conclusion, rapamycin treatment in mice (and perhaps in humans) promotes metastasis and the effect may be offset by treatment with a DC-based cancer vaccine.

Original languageEnglish
Article numbere0138335
JournalPLoS One
Volume10
Issue number10
DOIs
Publication statusPublished - Oct 1 2015

Fingerprint

Sirolimus
dendritic cells
metastasis
Dendritic Cells
Tumors
Vaccines
vaccines
Neoplasm Metastasis
neoplasms
mice
Neoplasms
immunosuppressive agents
Cancer Vaccines
Cell death
Immunosuppressive Agents
cell death
Bearings (structural)
Cell Death
Cells
organ transplantation

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Lin, T-J., Liang, W. M., Hsiao, P. W., Pradeep, M. S., Wei, W. C., Lin, H. T., ... Yang, N. S. (2015). Rapamycin promotes mouse 4T1 tumor metastasis that can be reversed by a dendritic cell-based vaccine. PLoS One, 10(10), [e0138335]. https://doi.org/10.1371/journal.pone.0138335

Rapamycin promotes mouse 4T1 tumor metastasis that can be reversed by a dendritic cell-based vaccine. / Lin, Tien-Jen; Liang, Wen Miin; Hsiao, Pei Wen; Pradeep, M. S.; Wei, Wen Chi; Lin, Hsin Ting; Yin, Shu Yi; Yang, Ning Sun.

In: PLoS One, Vol. 10, No. 10, e0138335, 01.10.2015.

Research output: Contribution to journalArticle

Lin, T-J, Liang, WM, Hsiao, PW, Pradeep, MS, Wei, WC, Lin, HT, Yin, SY & Yang, NS 2015, 'Rapamycin promotes mouse 4T1 tumor metastasis that can be reversed by a dendritic cell-based vaccine', PLoS One, vol. 10, no. 10, e0138335. https://doi.org/10.1371/journal.pone.0138335
Lin, Tien-Jen ; Liang, Wen Miin ; Hsiao, Pei Wen ; Pradeep, M. S. ; Wei, Wen Chi ; Lin, Hsin Ting ; Yin, Shu Yi ; Yang, Ning Sun. / Rapamycin promotes mouse 4T1 tumor metastasis that can be reversed by a dendritic cell-based vaccine. In: PLoS One. 2015 ; Vol. 10, No. 10.
@article{191f45bd44c04a1e937a2f2bc9bc8915,
title = "Rapamycin promotes mouse 4T1 tumor metastasis that can be reversed by a dendritic cell-based vaccine",
abstract = "Suppression of tumor metastasis is a key strategy for successful cancer interventions. Previous studies indicated that rapamycin (sirolimus) may promote tumor regression activity or enhance immune response against tumor targets. However, rapamycin also exhibits immunosuppressant effects and is hence used clinically as an organ transplantation drug. We hypothesized that the immunosuppressive activities of rapamycin might also negatively mediate host immunity, resulting in promotion of tumor metastasis. In this study, the effects of rapamycin and phytochemical shikonin were investigated in vitro and in vivo in a 4T1 mouse mammary tumor model through quantitative assessment of immunogenic cell death (ICD), autophagy, tumor growth and metastasis. Tumor-bearing mice were immunized with test vaccines to monitor their effect on tumor metastasis. We found that intraperitoneal (ip) administration of rapamycin after a tumor-resection surgery drastically increased the metastatic activity of 4T1 tumors. Possible correlation of this finding to human cancers was suggested by epidemiological analysis of data from Taiwan's National Health Insurance Research Database (NHIRD). Since our previous studies showed that modified tumor cell lysate (TCL)-pulsed, dendritic cell (DC)-based cancer vaccines can effectively suppress metastasis in mouse tumor models, we assessed whether such vaccines may help offset this rapamycin-promoted metastasis. We observed that shikonin efficiently induced ICD of 4T1 cells in culture, and DC vaccines pulsed with shikonin-treated TCL (SK-TCL-DC) significantly suppressed rapamycin-enhanced metastasis and Treg cell expansion in test mice. In conclusion, rapamycin treatment in mice (and perhaps in humans) promotes metastasis and the effect may be offset by treatment with a DC-based cancer vaccine.",
author = "Tien-Jen Lin and Liang, {Wen Miin} and Hsiao, {Pei Wen} and Pradeep, {M. S.} and Wei, {Wen Chi} and Lin, {Hsin Ting} and Yin, {Shu Yi} and Yang, {Ning Sun}",
year = "2015",
month = "10",
day = "1",
doi = "10.1371/journal.pone.0138335",
language = "English",
volume = "10",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "10",

}

TY - JOUR

T1 - Rapamycin promotes mouse 4T1 tumor metastasis that can be reversed by a dendritic cell-based vaccine

AU - Lin, Tien-Jen

AU - Liang, Wen Miin

AU - Hsiao, Pei Wen

AU - Pradeep, M. S.

AU - Wei, Wen Chi

AU - Lin, Hsin Ting

AU - Yin, Shu Yi

AU - Yang, Ning Sun

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Suppression of tumor metastasis is a key strategy for successful cancer interventions. Previous studies indicated that rapamycin (sirolimus) may promote tumor regression activity or enhance immune response against tumor targets. However, rapamycin also exhibits immunosuppressant effects and is hence used clinically as an organ transplantation drug. We hypothesized that the immunosuppressive activities of rapamycin might also negatively mediate host immunity, resulting in promotion of tumor metastasis. In this study, the effects of rapamycin and phytochemical shikonin were investigated in vitro and in vivo in a 4T1 mouse mammary tumor model through quantitative assessment of immunogenic cell death (ICD), autophagy, tumor growth and metastasis. Tumor-bearing mice were immunized with test vaccines to monitor their effect on tumor metastasis. We found that intraperitoneal (ip) administration of rapamycin after a tumor-resection surgery drastically increased the metastatic activity of 4T1 tumors. Possible correlation of this finding to human cancers was suggested by epidemiological analysis of data from Taiwan's National Health Insurance Research Database (NHIRD). Since our previous studies showed that modified tumor cell lysate (TCL)-pulsed, dendritic cell (DC)-based cancer vaccines can effectively suppress metastasis in mouse tumor models, we assessed whether such vaccines may help offset this rapamycin-promoted metastasis. We observed that shikonin efficiently induced ICD of 4T1 cells in culture, and DC vaccines pulsed with shikonin-treated TCL (SK-TCL-DC) significantly suppressed rapamycin-enhanced metastasis and Treg cell expansion in test mice. In conclusion, rapamycin treatment in mice (and perhaps in humans) promotes metastasis and the effect may be offset by treatment with a DC-based cancer vaccine.

AB - Suppression of tumor metastasis is a key strategy for successful cancer interventions. Previous studies indicated that rapamycin (sirolimus) may promote tumor regression activity or enhance immune response against tumor targets. However, rapamycin also exhibits immunosuppressant effects and is hence used clinically as an organ transplantation drug. We hypothesized that the immunosuppressive activities of rapamycin might also negatively mediate host immunity, resulting in promotion of tumor metastasis. In this study, the effects of rapamycin and phytochemical shikonin were investigated in vitro and in vivo in a 4T1 mouse mammary tumor model through quantitative assessment of immunogenic cell death (ICD), autophagy, tumor growth and metastasis. Tumor-bearing mice were immunized with test vaccines to monitor their effect on tumor metastasis. We found that intraperitoneal (ip) administration of rapamycin after a tumor-resection surgery drastically increased the metastatic activity of 4T1 tumors. Possible correlation of this finding to human cancers was suggested by epidemiological analysis of data from Taiwan's National Health Insurance Research Database (NHIRD). Since our previous studies showed that modified tumor cell lysate (TCL)-pulsed, dendritic cell (DC)-based cancer vaccines can effectively suppress metastasis in mouse tumor models, we assessed whether such vaccines may help offset this rapamycin-promoted metastasis. We observed that shikonin efficiently induced ICD of 4T1 cells in culture, and DC vaccines pulsed with shikonin-treated TCL (SK-TCL-DC) significantly suppressed rapamycin-enhanced metastasis and Treg cell expansion in test mice. In conclusion, rapamycin treatment in mice (and perhaps in humans) promotes metastasis and the effect may be offset by treatment with a DC-based cancer vaccine.

UR - http://www.scopus.com/inward/record.url?scp=84947205844&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947205844&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0138335

DO - 10.1371/journal.pone.0138335

M3 - Article

C2 - 26426423

AN - SCOPUS:84947205844

VL - 10

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 10

M1 - e0138335

ER -